



## **Hollister Biosciences Inc. Announces Stock Option Grant**

Vancouver, BC, June 1<sup>st</sup>, 2021 – **Hollister Biosciences Inc.** (CSE: **HOLL**, OTC: **HSTRF**, FRANKFURT: **HOB**) (the “**Company**”, “**Hollister Cannabis Co.**” or “**Hollister**”) a diversified cannabis branding company with products in over 280 dispensaries throughout California, and over 95 dispensaries throughout Arizona, is pleased to announce it has granted stock options to officers, employees and consultants of the Company under its stock option plan to acquire a total of 5,765,000 common shares of the Company. All of the options are exercisable at a price of \$0.40 per share and all of the options will vest on a quarterly basis. The options have a term of five (5) years and are subject in all respects to the terms of the Company's stock option plan and the policies of the CSE.

### **About Hollister Biosciences Inc.**

Hollister Biosciences Inc. is a multi-state company with a portfolio of innovative, high-quality cannabis & hemp branded consumer products and white-labeling manufacturing. Our products are sold in 370 dispensaries across Arizona and California. Hollister Biosciences wholly-owned brand, Venom Extracts, is a category-leading brand that sold more than 4 million grams in 2020, accounting for up to 30 percent of category sales in Arizona.

Products from Hollister Biosciences Inc. include HashBone, the brand's premier artisanal hash-infused pre-roll, along with concentrates (shatter, budder, crumble), distillates, solvent-free bubble hash, pre-packaged flower, pre-rolls, tinctures, vape products and full-spectrum high CBD pet tinctures. Our wholly-owned California subsidiary Hollister Cannabis Co is the 1st state and locally licensed cannabis company in the city of Hollister, CA, birthplace of the “American Biker”.

**Website:** [www.hollisterbiosciences.co](http://www.hollisterbiosciences.co)

**HOLLISTER BIOSCIENCES INC.:**

**Company Contact:**

**Melanie Barbeau:** [ir@hollisterbiosciences.co](mailto:ir@hollisterbiosciences.co)  
**Tel:** (416) 644-2020 or (212) 812-7680

*The CSE, nor its regulation services provider, does not accept responsibility for the adequacy or accuracy of this release.*

*Forward-Looking Information: This news release includes certain statements that may be deemed “forward-looking statements”. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “would”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on [www.sedar.com](http://www.sedar.com)*